Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 weeks. Shares are down 34% over that period as of the Feb. 13 close. The new year hasn’t provided a respite, with shares down over 8%. Shares are now trading less than 1% above their 52-week low.
This big drop raises the question: Have shares of this pharma stock become attractive? Some big-bank analysts give a resounding yes to that question. I’ll analyze key metrics from the company’s better-than-expected recent financial report, along with other important developments to give my take.
